JP2017505321A - 異常な細胞成長を処置するための方法および組成物 - Google Patents

異常な細胞成長を処置するための方法および組成物 Download PDF

Info

Publication number
JP2017505321A
JP2017505321A JP2016550218A JP2016550218A JP2017505321A JP 2017505321 A JP2017505321 A JP 2017505321A JP 2016550218 A JP2016550218 A JP 2016550218A JP 2016550218 A JP2016550218 A JP 2016550218A JP 2017505321 A JP2017505321 A JP 2017505321A
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
administered
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016550218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505321A5 (2
Inventor
ジョナサン エー． パクター，
ジョナサン エー． パクター，
ウィニー タム，
ウィニー タム，
チュンリ シュウ，
チュンリ シュウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of JP2017505321A publication Critical patent/JP2017505321A/ja
Publication of JP2017505321A5 publication Critical patent/JP2017505321A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
JP2016550218A 2014-02-07 2015-02-06 異常な細胞成長を処置するための方法および組成物 Withdrawn JP2017505321A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937253P 2014-02-07 2014-02-07
US61/937,253 2014-02-07
PCT/US2015/014843 WO2015120289A1 (en) 2014-02-07 2015-02-06 Methods and compositions for treating abnormal cell growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020034703A Division JP7289807B2 (ja) 2014-02-07 2020-03-02 異常な細胞成長を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2017505321A true JP2017505321A (ja) 2017-02-16
JP2017505321A5 JP2017505321A5 (2) 2018-03-22

Family

ID=53778481

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016550218A Withdrawn JP2017505321A (ja) 2014-02-07 2015-02-06 異常な細胞成長を処置するための方法および組成物
JP2020034703A Active JP7289807B2 (ja) 2014-02-07 2020-03-02 異常な細胞成長を処置するための方法および組成物
JP2022098159A Active JP7578643B2 (ja) 2014-02-07 2022-06-17 異常な細胞成長を処置するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020034703A Active JP7289807B2 (ja) 2014-02-07 2020-03-02 異常な細胞成長を処置するための方法および組成物
JP2022098159A Active JP7578643B2 (ja) 2014-02-07 2022-06-17 異常な細胞成長を処置するための方法および組成物

Country Status (7)

Country Link
US (4) US9962385B2 (2)
EP (2) EP3102232B1 (2)
JP (3) JP2017505321A (2)
DK (2) DK3102232T3 (2)
ES (2) ES2779975T3 (2)
FI (1) FI3698790T3 (2)
WO (1) WO2015120289A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022172480A (ja) * 2019-09-13 2022-11-17 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
JP2023534009A (ja) * 2020-07-13 2023-08-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
US12509450B2 (en) 2022-06-07 2025-12-30 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3091981B1 (en) * 2014-01-09 2021-03-10 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
US10532056B2 (en) 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US20200046700A1 (en) * 2017-02-13 2020-02-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
IL257225A (en) * 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
CA3130930A1 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
US20220249484A1 (en) * 2019-05-17 2022-08-11 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of cancer to ferroptosis-inducing therapies
AU2020297587B2 (en) 2019-06-21 2026-03-19 Pattern Computer, Inc. Therapeutic compositions and methods for treating cancers
EP4062914A4 (en) * 2019-11-18 2024-01-17 Inxmed (Nanjing) Co., Ltd. USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.
AU2021206684B2 (en) 2020-01-10 2024-01-18 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
WO2021154929A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
EP4101453A4 (en) 2020-02-05 2024-05-15 Inxmed (Nanjing) Co., Ltd. COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
JP2024505680A (ja) * 2021-02-05 2024-02-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678215B (zh) * 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CA2776944A1 (en) * 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
BR112014028376A2 (pt) * 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
WO2014059095A1 (en) * 2012-10-12 2014-04-17 Glaxosmithkline Llc Combinations

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ＡＮＴＩＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, vol. Ｖｏｌ．２６，Ｎｏ．２Ａ, JPN6018043349, 2006, pages 809 - 821, ISSN: 0004143239 *
ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, vol. 17, no. 23, JPN6018043353, 2011, pages 7219 - 7223, ISSN: 0004143243 *
ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, vol. Ｖｏｌ．１９，Ｎｏ．１９ Ｓｕｐｐｌ．, JPN6018043339, 2013, pages 39, ISSN: 0004143231 *
ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＯＮＣＯＬＯＧＹ, vol. 41, no. 2, JPN6018043358, 2012, pages 449 - 456, ISSN: 0004143238 *
ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＩＮＶＥＳＴＩＧＡＴＩＯＮ, vol. 124, no. 1, JPN6018043335, January 2014 (2014-01-01), pages 156 - 168, ISSN: 0004143228 *
ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＯＮＣＯＬＯＧＹ, vol. Ｖｏｌ．３１，Ｎｏ．１５ Ｓｕｐｐｌ．, JPN6018043336, 2013, pages 13523, ISSN: 0004143229 *
ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＯＮＣＯＬＯＧＹ, vol. Ｖｏｌ．３１，Ｎｏ．１５ Ｓｕｐｐｌ．, JPN6018043344, 2013, pages 18541, ISSN: 0004143235 *
ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＯＮＣＯＬＯＧＹ, vol. Ｖｏｌ．３１，Ｎｏ．１５ Ｓｕｐｐｌ．, JPN6018043347, 2013, pages 18557, ISSN: 0004143237 *
ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＯＮＣＯＬＯＧＹ, vol. Ｖｏｌ．３１，Ｎｏ．１５ Ｓｕｐｐｌ．, JPN6018043352, 2013, pages 2530, ISSN: 0004143242 *
ＪＯＵＲＮＡＬ ＯＦ ＨＥＭＡＴＯＬＯＧＹ ＡＮＤ ＯＮＣＯＬＯＧＹ, vol. 6, no. 27, JPN6018043350, 2013, pages 1 - 11, ISSN: 0004143240 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. 11, no. 3, JPN6018043356, 2012, pages 720 - 729, ISSN: 0003913002 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. Ｖｏｌ．１２，Ｎｏ．１１ Ｓｕｐｐｌ．, JPN6018043338, 2013, pages 283, ISSN: 0004143230 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. Ｖｏｌ．１２，Ｎｏ．１１ Ｓｕｐｐｌ．, JPN6018043340, 2013, pages 271, ISSN: 0004143232 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. Ｖｏｌ．１２，Ｎｏ．１１ Ｓｕｐｐｌ．, JPN6018043341, 2013, pages 69, ISSN: 0004143233 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. Ｖｏｌ．１２，Ｎｏ．１１ Ｓｕｐｐｌ．, JPN6018043342, 2013, pages 262, ISSN: 0004143234 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. Ｖｏｌ．１２，Ｎｏ．１１ Ｓｕｐｐｌ．, JPN6018043346, 2013, pages 31, ISSN: 0004143236 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. Ｖｏｌ．１２，Ｎｏ．１１ Ｓｕｐｐｌ．, JPN6018043351, 2013, pages 75, ISSN: 0004143241 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022172480A (ja) * 2019-09-13 2022-11-17 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
JP7634351B2 (ja) 2019-09-13 2025-02-21 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
US12280050B2 (en) 2019-09-13 2025-04-22 The Institute Of Cancer Research: Royal Cancer Hospital Therapeutic compositions, combinations, and methods of use
JP2023534009A (ja) * 2020-07-13 2023-08-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
US12509450B2 (en) 2022-06-07 2025-12-30 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
US10406158B2 (en) 2019-09-10
US20190046531A1 (en) 2019-02-14
FI3698790T3 (fi) 2023-06-06
HK1232152A1 (en) 2018-01-05
DK3102232T3 (da) 2020-04-20
US9962385B2 (en) 2018-05-08
JP7578643B2 (ja) 2024-11-06
JP2022113886A (ja) 2022-08-04
WO2015120289A1 (en) 2015-08-13
EP3102232A4 (en) 2017-09-27
DK3698790T3 (da) 2023-06-19
EP3102232B1 (en) 2020-02-05
JP2020079320A (ja) 2020-05-28
ES2779975T3 (es) 2020-08-21
US20160346282A1 (en) 2016-12-01
EP3102232A1 (en) 2016-12-14
US20230321097A1 (en) 2023-10-12
ES2945387T3 (es) 2023-06-30
EP3698790B1 (en) 2023-04-05
US20200147080A1 (en) 2020-05-14
JP7289807B2 (ja) 2023-06-12
EP3698790A1 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
JP7578643B2 (ja) 異常な細胞成長を処置するための方法および組成物
EP4096671B1 (en) Combination therapy for treating abnormal cell growth
JP7634351B2 (ja) 治療組成物、組み合わせ、及び使用方法
JP2023534009A (ja) 異常な細胞成長を処置するための併用療法
JP2022172480A5 (2)
JP2024528039A (ja) 異常な細胞成長を処置するための組み合わせ治療
HK40036798A (en) Methods for treating abnormal cell growth
HK40075762A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
HK1232152B (en) Methods and compositions for treating abnormal cell growth

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190503

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200317

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200323